Non-antibiotic intervention of chlamydial infection
View Patent ↗Methods for treating or reducing the risk of transmission of chlamydia to a recipient by topically applying a metalloprotease inhibitor to a site on the recipient which is likely to be exposed to Chlamydia . Topical compositions containing metalloprotease inhibitors are also disclosed for treating or reducing the risk of transmission of Chlamydia , as well as barrier contraceptive devices coated therewith.
1. A method for treating chlamydial infection comprising applying a treatment effective amount of a hydroxamate metalloprotease inhibitor to a portion of a patient's body infected by Chlamydia .
2. The method of claim 1 wherein said metalloprotease inhibitor is selected from the group consisting of N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide and N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine amide.
3. The method of claim 1 wherein said metalloprotease inhibitor is from about 0.00005% to about 5% by weight of the composition.
4. The method of claim 1 wherein said metalloprotease inhibitor is incorporated into a topical composition comprising a pharmaceutically acceptable aqueous solution, non-aqueous solution, suspension, ointment, jelly, insert, suppository, sponge, salve, cream, foam, foaming tablet, or douche.
5. The method of claim 1 wherein the composition is applied intravaginally.
6. The method of claim 1 wherein the composition is applied from about 1 hour before to about 6 hours after exposure to Chlamydia .
7. The method of claim 1 wherein the composition is applied with an applicator or an intravaginal delivery device.
8. The method of claim 7 wherein the applicator or intravaginal delivery device is a barrier contraceptive.
9. The method of claim 1 wherein the chlamydial infection is selected from the group consisting of chlamydial eye diseases, sexually transmitted chlamydial infections, complications of sexually transmitted chlamydial infections, and chlamydial pneumonia.
10. A method for treating Chlamydia infection in a subject at risk comprising (a) applying a topical composition comprising an effective amount of a hydroxamate metalloprotease inhibitor to an area of said subject at risk for exposure to Chlamydia , and (b) inhibiting Chlamydia growth in said area.
11. A method for treating Chlamydia infection in a subject in need thereof comprising (a) identifying a subject suffering from Chlamydia infection, (b) topically applying a composition comprising an effective amount of a hydroxamate metalloprotease inhibitor and a pharmaceutically acceptable carrier to an area of said subject infected with Chlamydia .
12. The method of claim 2 , 10 , or 11 wherein said hydroxamate metalloprotease inhibitor is N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L -tryptophanmethylamide.